Nivolumab Plus Chemotherapy Prolongs Survival in Advanced Gastric Cancer
Markus Moehler, MD, PhD, discusses the survival outcomes of nivolumab in combination with chemotherapy in patients with advanced gastric cancer.
Markus Moehler, MD, PhD, the head of Gastrointestinal Oncology at Mainz University Clinic, discusses the survival outcomes of nivolumab (Opdivo) in combination with chemotherapy in patients with advanced gastric cancer.
In the CHECKMATE-649 study (NCT02872116), overall survival (OS) and progression-free survival (PFS) were improved with nivolumab/chemotherapy compared with chemotherapy alone in patients with advanced gastric cancer. In the primary population, where patients had a PD-L1 tumor proportion score of 5 or higher, the median OS improved from 11.1 to 14.4 months, according to Moehler.
Additionally, OS for all randomized patients proved significant. In the PD-L1-postive group, PFS benchmarks were highly met. Additionally, the 1-year survival rate increased from 46% to 57% with the combination.
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
April 10th 2024During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.
Read More
The Impact of the Gut Microbiome in Young Patients With Colorectal Cancer
February 15th 2021In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.
Listen
